Morning Briefing
Summaries of health policy coverage from major news organizations
Candy-Flavored Amphetamine Hits Market Amid Controversy
Adzenys is geared toward treating children with ADHD, but experts worry that the chewable, fruity medication is problematic as the line between need and want for those types of drugs is increasingly blurry.
STAT: It's Tasty And Easy To Take. And That's Why A New ADHD Drug Alarms Some Psychiatrists.
There’s a new, candy-flavored amphetamine on the market. Adzenys, as the chewable, fruity medication is called, packs the punch of Adderall and is geared toward children with attention deficit hyperactivity disorder. The drug hit the market last week and is already stirring controversy: Some psychiatrists worry that Adzenys will accelerate a trend toward overmedicating kids — and could be yet another gateway into ADHD drug abuse. (Keshavan, 5/23)
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
